EP0273566A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Anti-human IgM immunoadsorbent and process for producing said immunoadsorbent
Assignee: Imre Corp
•
Filing: 1987-11-17
•
Granted: —
•
Expires: 2007-11-17
Abstract
Abstract An immunoadsorbent material for removing IgM and IgM-complexes from biological fluids is prepared by covalently binding anti-IgM antibodies to a solid-phase silica matrix. It has been found that reacting hydroxyl-derivatized silica in the presence of cyanogen bromide with the anti-IgM antibodies provides a particularly stable, high-capacity immunoadsorbent. The immunoadsorbent material may be employed in a column for therapeutic treatment of various disorders, such as primary biliary cirrhosis.
Inventors
- 👤 Joseph P. Balint
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 09:21
CPC Classifications
A; A61; A61M; A61M1/00; A61M1/36; A61M1/3679; A61P; A61P1/00; A61P1/16; A61P39/00; A61P39/02; B; B01; B01J; B01J20/00; B01J20/02; B01J20/10; B01J20/103; B01J20/28; B01J20/28002; B01J20/28004; B01J20/30; B01J20/3071; B01J20/3085; B01J20/3092; B01J20/32; B01J20/3202; B01J20/3204; B01J20/3214; B01J20/3217; B01J20/3219; B01J20/3231; B01J20/3242; B01J20/3244; B01J20/3246; B01J20/3248; B01J20/3257; B01J20/3268; B01J20/3272; B01J20/3274; B01J2220/00; B01J2220/50; B01J2220/58; B01J2220/66
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
70 words
A method for preparing an immunoadsorbent material useful for removing IgM and IgM-related complexes from biological fluids, said method comprising: introducing free hydroxyl groups onto a silica matrix; activating the hydroxyl groups on silica matrix in the presence of cyanogen bromide at a pH in the range from 11.0 to 11.5; and reacting the activated silica matrix with anti-IgM antibody to covalently link the antibody to the activated silica substrate.
Claim 2
Independent Claim
70 words
A method for preparing an immunoadsorbent material useful for removing IgM and IgM-related complexes from biological fluids, said method comprising: introducing free hydroxyl groups onto a silica matrix; activating the hydroxyl groups on silica matrix in the presence of cyanogen bromide at a pH in the range from 11.0 to 11.5; and reacting the activated silica matrix with anti-IgM antibody to covalently link the antibody to the activated silica substrate.
Claim 3
Dependent Claim
17 words
A method according to Claim 1, wherein the hydroxyl groups are introduced by reaction with a silane.
Claim 4
Dependent Claim
11 words
A method according to Claim 2, wherein the silane is γ-aminopropyltriethoxysilane.
Claim 5
Dependent Claim
30 words
An immunoadsorbent material useful for removing IgM and IgM-complexes from biological fluids, said immunoadsorbent comprising anti-IgM antibody covalently bound to a silica matrix through hydroxyl groups activated with cyanogen bromide.
Claim 6
Dependent Claim
30 words
An immunoadsorbent material useful for removing IgM and IgM-complexes from biological fluids, said immunoadsorbent comprising anti-IgM antibody covalently bound to a silica matrix through hydroxyl groups activated with cyanogen bromide.
Claim 7
Dependent Claim
21 words
An immunoadsorbent material according to Claim 4, wherein the hydroxyl groups are introduced to the silica matrix by reaction with γ-aminopropyltriethoxysilane.
Claim 8
Independent Claim
19 words
A method or material according to any one of the preceding claims, wherein the silica matrix is amorphous silica.
Claim 9
Dependent Claim
14 words
A method or material according to Claim 6, wherein the amorphous silica is diatomite.
Claim 10
Dependent Claim
16 words
A method or material according to Claim 7, wherein the diatomite is 45 to 60 mesh.
Claim 11
Dependent Claim
37 words
A system for removing IgM and IgM-related complexes from biological fluids, said system comprising: an enclosure having an inlet and an outlet defining a chamber therebetween; and immunoadsorbent material according to Claim 4 packed inside said chamber.
References Cited (Backward Citations)
DE2042976A1
Cited
US3975511A
Cited
EP0088818A1
Cited
EP0131251A1
Cited
EP0175270A2
Cited
EP0183207A1
Cited
EP0237659A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.